Your search for smoking cessation returned 7 results

A study in The Lancet Respiratory Medicine suggests that the rate at which smokers metabolize nicotine could be a significant factor in guiding smoking cessation treatment.

The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) have issued a policy statement on the risks of electronic nicotine delivery systems (ENDS) and the potential benefits as a smoking cessation aid.

Although physicians often consider increasing a medication dose if there is no response to the standard dose in a patient, this strategy may not be effective with varenicline for smoking cessation.

A case report in the Journal of Pharmacy Practice is the first published instance of a patient that required >30% reduction in weekly warfarin dose after smoking cessation.

A new study explores the use of psilocybin, a 5HT2AR agonist, as an adjunct in smoking cessation treatment

Method: Data were analyzed for participants (n = 683) of a randomized controlled trial comparing the efficacy of different smoking cessation pharmacotherapies (Wisconsin, 2005–2008). Activity (assessed via pedometry) and body weight were measured in the days surrounding the quit day and again one year later, at which time 7-day point-prevalence abstinence from smoking was assessed.

Importance: Current tobacco use treatment approaches require smokers to request treatment or depend on the provider to initiate smoking cessation care and are therefore reactive. Objective: To assess the effect of a proactive, population-based tobacco cessation care model on use of evidence-based …